Journal Mobile Options
Table of Contents
Vol. 219, No. 1, 2009
Issue release date: June 2009
Add to my selection Citation Download
Free Access
Dermatology 2009;219:89–90
(DOI:10.1159/000207792)
Correspondence and Opinions

Bullous Pemphigoid Occurring during Efalizumab Treatment for Psoriasis: A Paradoxical Auto-Immune Reaction?

Monnier-Murina K. · Du Thanh A. · Merlet-Albran S. · Guillot B. · Dereure O.
Department of Dermatology, Hôpital Saint-Eloi, University of Montpellier I University Hospital, Montpellier, France Dermatology 2009;219:89–90 (DOI:10.1159/000207792)

First-Page Preview
Abstract of Correspondence and Opinions

 goto top of outline Author Contacts

O. Dereure
Department of Dermatology, Hôpital Saint-Eloi
80, avenue Augustin-Fliche
FR–34295 Montpellier Cedex 5 (France)
Tel. +33 467 33 69 06, Fax +33 467 33 69 58
E-Mail o-dereure@chu-montpellier.fr


 goto top of outline Article Information

Number of Print Pages : 2


 goto top of outline Publication Details

Dermatology

Vol. 219, No. 1, Year 2009 (Cover Date: June 2009)

Journal Editor: Saurat J.-H. (Geneva)
ISSN: 1018-8665 (Print), eISSN: 1421-9832 (Online)

For additional information: http://www.karger.com/DRM


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.